Sanofi, Elan rise on M&A talk

Sanofi-Aventis and Elan saw their stocks leap yesterday on deal rumors: Speculation that Sanofi may buy Merck's interest in its animal-health joint venture Merial sent its shares flying, while rumors that Pfizer might buy Elan boosted the Irish company's stock. Report | Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.